Cardurion Pharmaceuticals raised $260 million in a Series B financing led by Ascenta Capital with participation by NEA, GV, and others to advance its innovative medicines for cardiovascular diseases.
Cardurion Pharmaceuticals raised $260 million in a Series B financing led by Ascenta Capital with participation by NEA, GV, and others to advance its innovative medicines for cardiovascular diseases.
07/16/24, 1:13 PM
Location
burlingtonMoney raised
$260 million
Industry
science and engineering
data and analytics
health care
biotechnology
Round Type
series b
Investors
Bain Capital Private Equity, Bain Capital Life Sciences, Digitalis Ventures, Delos Capital, Blue Owl Healthcare Opportunities, Invus, Farallon Capital Management, Millennium Management, Fidelity Management & Research Company, Gv, Nea, Ascenta Capital
Cardurion Pharmaceuticals, Inc. announced a $260 million Series B financing led by Ascenta Capital, with participation by several new investors and existing ones. The proceeds will be used to support later-stage clinical trials, expand cardiovascular indications for the company’s drug candidates, progress internal discovery programs, and acquire additional therapeutic assets targeting unmet needs in the cardiovascular disease area.
Company Info
Location
78 blanchard road, suite 200
burlington, massachusetts, united states
Additional Info
Cardurion Pharmaceuticals is a next generation cardiovascular company focused on the discovery and development of novel therapeutics for the treatment of heart failure and other cardiovascular diseases. Led by an experienced team of CV experts and industry veterans, we are developing groundbreaking clinical programs in PDE9 and CaMKII inhibition. We take a strategic portfolio approach driven by in-house drug discovery and our office of strategy and have concluded foundational partnerships with key strategics and investors, including an up to $300 million dollar investment from Bain Capital to support current programs and pipeline growth. Cardurion Pharmaceuticals has facilities in Burlington, Massachusetts and Shonan, Japan.